Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. is announcing a planned Chief Financial Officer transition. Dave Denton will step down as CFO and leave Pfizer on August 15, 2026 to take a role in the consumer goods industry. The company states his departure is not related to Pfizer’s financial or operating results or any disagreements over financial, operational, accounting or reporting policies.
Pfizer has appointed Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer effective August 16, 2026, while it conducts a comprehensive internal and external search for a permanent successor. Guegan, 55, has more than two decades at Pfizer and recently led finance for the global biopharmaceutical business and played a key role in integrating Seagen into Pfizer in 2024.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 23 phantom stock units tied to Pfizer common stock at a reference price of $26.00 per unit. This award increases his phantom stock unit balance to 772,772 units, which are cash-settled after his separation from service.
Pfizer Inc. reported that SVP & Controller Jennifer B. Damico executed an open-market sale of 2,000 shares of Pfizer common stock on June 9, 2026 at $25.70 per share. Following this transaction, she directly holds 31,397 Pfizer common shares.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC Chairman & CEO Albert Bourla reported a compensation-related grant of 23 Phantom Stock Units SSP linked to common stock. The units were awarded at a reference price of $26.18 per unit and increase his directly held phantom stock balance to 772,789 units.
Each phantom unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These units are settled in cash after his separation from service and may be moved into an alternative investment account at any time, so they do not represent an open-market stock purchase or sale.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on common stock equivalents. Each unit represents one phantom share of Pfizer common stock, with the grant recorded at $25.33 per unit.
These units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and can be moved into an alternative investment account at any time. Following this grant, his reported phantom stock unit balance is 773,297 units.
Pfizer Inc filed a Form 13F as an institutional investment manager reporting holdings. The report lists 21 Form 13F information table entries with a total value of $238,775,816. The filing is signed by Madelyn D. Purcell with a signature date of 05-12-2026.
Pfizer Inc. reported first‑quarter 2026 results showing modest growth in sales but lower earnings. Total revenues were $14,451 million, up from $13,715 million a year earlier, driven by higher product, alliance and royalty revenues.
Income from continuing operations was $2,709 million versus $2,973 million, and diluted EPS was $0.47 compared with $0.52. Operating cash flow was $2,615 million, and cash and cash equivalents rose to $1,703 million. At April 29, 2026, 5,699,444,169 common shares were outstanding.
The balance sheet showed total assets of $207,618 million and long‑term debt of $60,565 million. Pfizer highlighted its $8.0 billion Metsera acquisition, ongoing multi‑year cost‑reduction and manufacturing optimization programs, and restructuring and acquisition‑related costs of $195 million in the quarter.
Pfizer Inc. reported first-quarter 2026 results and reaffirmed its full‑year 2026 financial guidance. Revenues were $14.5 billion, up 5% year over year (2% operational), with 7% operational growth excluding Comirnaty and Paxlovid, and 22% operational growth from launched and acquired products.
Reported diluted EPS was $0.47 versus $0.52 a year ago, while adjusted diluted EPS was $0.75 versus $0.92, reflecting higher cost of sales, increased R&D and acquired IPR&D expenses. Pfizer maintained 2026 revenue guidance of $59.5–$62.5 billion and adjusted diluted EPS guidance of $2.80–$3.00, invested $2.5 billion in internal R&D and returned $2.4 billion in dividends. Recent developments include strong growth in products such as Padcev, Eliquis and oncology biosimilars, positive Phase 2/3 readouts across several pipeline programs, a $1.875 billion exit from its ViiV Healthcare stake, and Vyndamax patent settlements extending effective U.S. patent expiry to June 1, 2031.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 22 Phantom Stock Units linked to Pfizer common stock on April 30, 2026. Each unit represents one phantom share of common stock and is part of a deferred compensation arrangement, not an open-market stock purchase.
The units were awarded under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash after his separation from service. Following this grant, Bourla holds a total of 760,229 Phantom Stock Units directly under this plan.